/Investor DB

SV Life Sciences — 2017 Investments

3 investments dated 2017 · listed companies and verified rows first · show all

TransEnterixtransenterix.cominSep 2017SEC filingmedium confidence

Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.

AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US

Anthony Fernando(Executive Officer)inTodd M. Pope(Executive Officer, Director)inJoseph P Slattery(Executive Officer)inJames J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)Jeffrey G. Spragens(Executive Officer, Director)

Board seatDavid B Milne· per SEC Form D · $950K raise · filed Sep 2017

Co-investorsAisling CapitalHercules Capital, Inc.Saints CapitalSV Health InvestorsQuaker BioVentures

Bardybardydx.cominJan 2017Acquired

BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.

Digital HealthHealthtechMedical DevicesSeattle, US

Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)

Co-investorsAPERTURE Venture PartnersAphelion CapitalAscension VenturesLumira VenturesRC CapitalRex Health Ventures+2 more

Pulmocidepulmocide.cominMar 2017 · $30.4M

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin

Co-investorsAdjuvant CapitalAsahi Kasei Corporate Venture CapitalDementia Discovery FundF-Prime CapitalJeito CapitalLongwood Fund+4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.